+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cellectis Inc - logo

Cellectis is a gene-editing company that develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company designs novel products including immune therapies for cancer and enzymes which can add DNA at targeted places in genomes. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies which develop in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia. Cellectis S.A. was founded in 1999 and is based in Paris, France.

From
From
From
From
Cell and Gene Therapy CROs Market, 2018-2030 - Product Thumbnail Image

Cell and Gene Therapy CROs Market, 2018-2030

  • Report
  • October 2018
  • 238 Pages
From
From
From
Gene Therapy Market (3rd Edition), 2019-2030 - Product Thumbnail Image

Gene Therapy Market (3rd Edition), 2019-2030

  • Report
  • August 2019
  • 550 Pages
From
From
From
From
CRISPR Technology: Global Markets - Product Thumbnail Image

CRISPR Technology: Global Markets

  • Report
  • May 2020
  • 83 Pages
From
From
From
Global DNA Read, Write and Edit Market - Product Thumbnail Image

Global DNA Read, Write and Edit Market

  • Report
  • September 2019
  • 399 Pages
From
Loading Indicator
adroll